

Increased rate of major malformations in offspring exposed to valproate during pregnancy

D.F. Wyszynski, MD, PhD; M. Nambisan, MPH; T. Surve, MPH; R.M. Alsdorf, BA; C.R. Smith, MPH; and L.B. Holmes, MD, for the Antiepileptic Drug Pregnancy Registry

Abstract—Objective: To determine the rate of occurrence of major malformations in infants whose mothers had taken the drug valproic acid (VPA) as monotherapy during the first trimester of pregnancy and had enrolled in the North American Antiepileptic Drug Pregnancy Registry. **Methods:** Data were collected from pregnant women throughout the United States and Canada through telephone-based interviews. Each woman was interviewed at enrollment, at 7 months' gestation, and postpartum. With her written permission, the medical records of each mother and her infant were obtained. The major malformations tabulated were those identified at or before 5 days of age. The prevalence of congenital malformations among offspring of monotherapy VPA-exposed women was compared with that among infants of women exposed to all other antiepileptic drugs (internal comparison group) and with that among newborns in the Active Malformations Surveillance Program at Brigham and Women's Hospital (external comparison group). **Results:** Sixteen affected cases were identified among 149 VPA-exposed women (proportion: 10.7%; 95% CI: 6.3 to 16.9%). The prevalence in the internal comparison group was 2.9% (95% CI: 2.0 to 4.1%; odds ratio: 4.0, 95% CI: 2.1 to 7.4; $p < 0.001$). Assuming a 1.62% prevalence in the external comparison group, the relative risk of having an affected offspring for VPA-exposed women was 7.3 (95% CI: 4.4 to 12.2; $p < 0.001$). **Conclusion:** Maternal exposure to valproic acid during the first trimester of pregnancy significantly increased the risk of major malformations.

NEUROLOGY 2005;64:961–965

Exposure to anticonvulsant drugs during pregnancy is potentially harmful to a fetus.¹ However, there are only a few well-designed prospective studies. Pregnancy registries are a new, efficient approach to obtaining information about the fetal effects of exposures to specific drugs as monotherapy.

Valproic acid (VPA) became available clinically in the United States in 1978 as an immediate-release formulation (Depakene Convulex capsule; Abbott Laboratories, Abbott Park, IL) for the treatment of absence seizures.^{2,3} In 1983, another formulation, divalproex sodium (Depakote; Abbott Laboratories), was introduced. It is an enteric-coated, stable coordination complex of VPA and valproate sodium. VPA is an 8-carbon two-chain fatty acid that is absorbed rapidly after oral administration and has a short half-life.⁵ Although VPA's mechanism of action is not established, it may increase brain concentrations of γ -aminobutyric acid.⁴ VPA use has expanded to include treatment of complex partial and other seizures, prevention of mi-

graine headache, and treatment of acute mania associated with bipolar disorder.⁶

A report suggesting teratogenicity of VPA in humans was published in 1980.⁷ In 1982, a significant (20-fold) risk for the occurrence of spina bifida after exposure to VPA during pregnancy was identified by a regional birth defects surveillance program.⁸ In 1984, the term "fetal valproate syndrome" was suggested to refer to a constellation of minor and major malformations⁹: a pattern of facial manifestations (epicanthal folds, flat nasal bridge, small upturned nose, long philtrum, and thin upper lip), multiple major malformations, and CNS dysfunction.¹⁰ Similar malformations occur in children exposed to other anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, but no systematic study has determined whether malformations in VPA-exposed children are distinctive. A common major malformation attributed to exposure to VPA was neural tube defects (NTDs).^{8,11–17} The risk of an NTD may be as

See also pages 938, 949, and 955

From the Genetics Program (Dr. Wyszynski, R.M. Alsdorf), Department of Medicine, Boston University School of Medicine, Department of Pediatrics (Dr. Holmes, M. Nambisan, T. Surve, and C.R. Smith), Harvard Medical School, and Genetics and Teratology Unit (Dr. Holmes), Pediatric Service, Massachusetts General Hospital, Boston, MA.

The Antiepileptic Drug Pregnancy Registry is funded by sponsorship grants in excess of \$10,000 received from each of the following: Abbott Laboratories, Elan Pharmaceuticals, GlaxoSmithKline, Novartis, Ortho-McNeil, and Pfizer Pharmaceuticals. Drs. Wyszynski and Holmes have received speaker fees from GlaxoSmithKline during 2004. R.M. Alsdorf was supported by an Undergraduate Research Opportunities Program Award from Boston University.

Received June 2, 2004. Accepted in final form December 1, 2004.

Address correspondence and reprint requests to Dr. D.F. Wyszynski, Boston University School of Medicine, 715 Albany St., L-320, Boston, MA 02118; e-mail: dfw@bu.edu

high as 5% at high VPA exposures.¹⁸ Other congenital malformations associated with this exposure have included heart defects, oral clefts, genital abnormalities, and limb defects.^{10,19-25}

We have performed a prospective study of the rate of occurrence of major malformations identified at birth in infants whose mothers had taken valproate as monotherapy and had enrolled in the North American Antiepileptic Drug (AED) Pregnancy Registry.

Methods. The North American AED Pregnancy Registry is an ongoing surveillance system of pregnant women exposed to anti-convulsant drugs.²⁶ Women were interviewed at enrollment, at 7 months' gestation, and postpartum. Medical records were obtained about the mother's medical history and any malformations identified in the infant. The protocol and criteria for the release of findings were established prospectively by an external Scientific Advisory Committee.²⁶ The informed consent document, read and signed by each woman who enrolls in the Registry, was reviewed and approved each year by the Human Studies Committee of the Massachusetts General Hospital.

Exposed participants. We studied only infants exposed to VPA monotherapy during the first trimester of pregnancy. We included elective abortions for structural abnormalities and stillbirths. To minimize recall bias, we included only women who did not know, at time of enrollment, whether the fetus had a malformation or not. We excluded women who enrolled with some knowledge of the status of the fetus, typically after having prenatal screening by ultrasound. Women who enrolled after having had prenatal screening by either chorionic villus screening or nuchal translucency were also excluded. A major malformation was defined as a structural abnormality with surgical, medical, or cosmetic importance.²⁷ Physical features not considered a major malformation were 1) minor anomalies; 2) deformations; 3) physiologic features due to complications of prematurity, such as undescended testes; 4) birth marks; 5) genetic disorders and chromosomal abnormalities; 6) any finding by prenatal sonography, such as absence of one kidney, that was not identified by an examining pediatrician; 7) an incidental finding within 5 days of delivery, at surgery or autopsy, such as a unilobe right lung, that had not been detected in clinical evaluations. The written descriptions of the findings from the examinations of each infant were reviewed separately by two registry dysmorphologists who were blinded to exposure status. Any disagreement was resolved by consensus.

Comparison groups. There were two comparison groups. The first, the internal comparison group, comprised infants of enrolled mothers who had taken any monotherapy AED, other than VPA, during the first trimester of gestation. The mothers in the internal comparison group, like the mothers taking VPA, were not aware of the health status of the fetus (i.e., presence or absence of a congenital anomaly) at the time of the baseline interview. The second comparison group, the external comparison group, comprised newborns with major anomalies identified in the Active Malformations Surveillance Program at Brigham and Women's Hospital in Boston, MA, which used the same inclusion/exclusion criteria as the registry.²⁸ For this comparison, the infants whose malformations were associated with chromosome abnormalities or a hereditary disorder were excluded.

Statistical methods. Statistical analyses were carried out with the software Stata (version 8.2).²⁹ For continuous data, means and standard deviations were calculated, and potential differences were tested with simple linear regression. In the case of ordinal variables, multiple logistic regression was used to obtain odds ratios (ORs) and their 95% CIs and to derive adjusted *p* values.

Results. Three thousand four hundred forty-one women enrolled in the AED Pregnancy Registry from February 1, 1997, through November 20, 2003. Fifty-seven percent of these women (*n* = 1,956) reported having taken an anti-convulsant drug as monotherapy during the first trimester

and reported having either a liveborn or stillborn infant or a pregnancy that was terminated electively because of a fetal abnormality. VPA monotherapy was used by 235 women (12.0% of monotherapy-exposed group of 1,956). One hundred forty-nine (63%) of these women were unaware of the health status of the fetus at the time of the baseline interview (i.e., "pure" prospective). These women constitute the "VPA-exposed" group.

Sixteen infants with confirmed major malformations (table 1) were identified in the VPA-exposed group (proportion: 10.7%; 95% CI: 6.3 to 16.9%). Two of the children (Cases 2,321 and 2,978) were African American, and 14 were Caucasian. All mothers had taken VPA because of seizures (mean age at first seizure 15 years, range 10 to 21 years). The average dosage of VPA used by mothers of malformed and nonmalformed infants was not different statistically (mothers of malformed infants: 1,033.3 mg, SD: 434 mg; mothers of nonmalformed infants: 983.2 mg, SD: 431 mg; *p* = 0.69). After excluding mothers of infants with the less severe malformations (Cases 2,118, 2,321, 2,364, 2,978, 3,225, and 3,560; see table 1), this comparison remained insignificant (*p* = 0.28). The mothers of all 16 infants took either prenatal vitamins/multivitamins or supplemental folic acid in the periconceptual period. The mother who had a baby with penoscrotal hypospadias was the only smoker in this group. She consumed 1 pack of cigarettes per day during the periconceptual period.

Twins 1,181a (male) and 1,181b (female) were dizygotic but concordant for their phenotype (lumbosacral spina bifida). Case 3,445 had a severe form of congenital heart defect (pulmonary atresia, ventricular septal defect [VSD], and tricuspid valve stenosis), which resulted in death 12 days after birth. Newborn 2,712 had multiple congenital anomalies, including VSD.

Internal comparison. The prevalence at birth of major malformations among the infants of the 149 VPA-exposed women was compared with that of 1,048 women exposed to all other AED monotherapies (internal comparison). The two groups were very similar in terms of their demographic characteristics and prenatal exposures (table 2). The prevalence of major malformations among the internal comparison group was 2.9% (95% CI: 2.0 to 4.1%). Therefore, there was a fourfold increased risk for having an offspring with a major birth defect for VPA-exposed women compared with those taking other AEDs (OR: 4.0; 95% CI: 2.1 to 7.4; *p* < 0.001).

External comparison. The number of newborns with major anomalies observed among VPA-exposed women was compared with the number of cases expected on the basis of prevalence in the Active Malformations Surveillance Program at Brigham and Women's Hospital²⁸ and other hypothetical alternative rates (i.e., from 2 to 7%). With use of the 1.62% population prevalence rate of nongenetic major malformations at Brigham and Women's Hospital, the relative risk of having an affected offspring among VPA-exposed women was 7.3, with 95% CI ranging from 4.4 to 12.2 (one sided *p* < 0.001). The risk continued to be significant if the population prevalence rate of major birth defects was <6.5%.

Discussion. The findings of this study show that the use of VPA during the first trimester of pregnancy significantly increased the risk of major con-

Table 1 Characteristics of cases with major congenital malformations exposed to valproic acid during early gestation

Study no.	Dosage at conception, mg	Birth status	Major malformation
1,085	1,000	Live	Tetralogy of Fallot, pulmonary atresia
1,181a	Epival 1000	Pregnancy terminated at 18 wk	Lumbosacral spina bifida, affected twins (diagnosed by ultrasound)
1,181b	Epival 1000	Pregnancy terminated at 18 wk	Lumbosacral spina bifida, affected twins (diagnosed by ultrasound)
2,118	1,000	Live	Atrial septal defect, bicuspid aortic valve
2,321	500	Live	Postaxial polydactyly, type B
2,364	750	Live	Bilateral inguinal hernia
2,414	2,000	Live	Lumbosacral spina bifida
2,547	1,500	Live	Hypospadias (penoscrotal location), microcephaly, and developmental delay*
2,712	1,250	Live	Multiple congenital malformations (including developmental delay, failure to thrive, hypotonia, mitral valve abnormality, triphalangeal thumbs)
2,978	750	Live	Equinovarus club foot deformity
2,997	750	Pregnancy terminated	Bilateral multicystic dysplastic kidneys (diagnosed by ultrasound)
3,225	1,375	Live	Penoscrotal hypospadias
3,445	250	Neonatal death at 12 d of age	Pulmonary atresia, VSD, tricuspid valve stenosis
3,456	750	Live	Bilateral inguinal hernia
3,560	750	Live	Lambdoid suture synostosis
3,858	Depakote sprinkles 125, 13×/d	Live	Metopic synostosis, multiple heart defects: VSD, pulmonary valve stenosis, atrial septal defect

* Developmental delay assessed during follow-up.

Epival = brand name for divalproex sodium in Canada; VSD = ventricular septal defect.

genital malformations. Our findings are also in agreement with several previous reports that showed that VPA was associated with adverse outcomes more frequently than other AEDs.^{17,30-35} Although most of these studies were carried out retrospectively, the findings have been remarkably consistent. One notable and new finding in our study was the occurrence in two infants of pulmonary atresia, a severe heart defect. The suggested increased frequency of craniosynostosis, especially metopic synostosis,³⁶ was validated.

There are several limitations of this study. First, for the external comparison control subjects from the Active Malformations Surveillance Program, the details available from the review of each infant's medical records were, on average, more extensive than the information obtained by the AED Pregnancy Registry by mail from the physician of the infant of the enrolled mother. To address this limitation, the AED Pregnancy Registry employs currently the same method of collecting information for both newly enrolled control subjects and anticonvulsant-exposed infants. A second limitation is the fact that the external control subjects from the Active Malformations Surveillance Program at Brigham and Women's Hos-

pital and the internal control subjects from the AED Pregnancy Registry did not include very many women with epilepsy (or a mood disorder) who were not being treated with anticonvulsant drugs during pregnancy, a theoretical confounder. Whereas at least one study³⁷ has suggested that women with epilepsy have an increased risk for having malformed infants, unrelated to the medication taken, several others^{1,38,39} do not support that hypothesis.

Third, another limitation of this, and other pregnancy exposure, registries is that initially the only outcome that can be assessed is the frequency of all malformations, not specific malformations, such as spina bifida, a well-known consequence of maternal exposure to VPA. To establish correlations, such as a threefold increase in the occurrence of a malformation with a frequency of 1 in 1,000 (like spina bifida or cleft lip), at least 8,329 monotherapy VPA-exposed infants of "pure" prospective mothers must be enrolled to establish this correlation with 80% power.²⁶ Fourth, the North American AED Pregnancy Registry relies on women who enroll voluntarily by calling the toll-free number to provide their exposure and outcome information. Other AED pregnancy registries (i.e., UK Epilepsy and Pregnancy Register,

Table 2 Comparison of maternal and newborn characteristics of women exposed to valproic acid and to all other antiepileptic monotherapy drugs during early pregnancy

Characteristic	Valproate, n = 149	All other AEDs, n = 1,048	Unadjusted odds ratio (95% CI)
Child male	80 (53.7)	536 (51.2)	1.1 (0.8–1.6)
Married	77 (76.2)	663 (89.4)	0.9 (0.8–0.9)
Mother's education			
≤grade 12	18 (24.0)	96 (18.3)	2.4 (0.9–5.8)
Some college, junior college graduate	19 (25.3)	140 (26.7)	1.7 (0.7–4.1)
College graduate, 4-y	30 (40.0)	186 (35.5)	2.1 (0.9–4.7)
Post college	8 (10.7)	102 (19.5)	Ref.
Maternal age, mean (SD); y	29 (6)	30 (5)	1.0 (0.9–1.0)
Gravida, mean (SD)	2 (1)	2 (1)	0.9 (0.8–1.0)
Child Caucasian	123 (83.1)	912 (88.7)	0.6 (0.4–1.0)
Father Caucasian	118 (80.3)	879 (85.6)	0.7 (0.4–1.1)
Age at first seizure, mean (SD); y	13.0 (6)	16.9 (8)	0.9 (0.9–0.9)
Seizures during pregnancy	33 (24.4)	358 (36.9)	0.6 (0.4–0.8)
Prenatal vitamins or multivitamins	115 (78.2)	861 (84.2)	0.7 (0.4–1.0)
Folic acid supplement	106 (71.6)	649 (63.8)	1.4 (0.9–2.0)
Cigarette smoking			
None	119 (79.9)	885 (86.4)	Ref.
>none to <½ pack	10 (6.7)	55 (5.4)	1.4 (0.6–2.6)
≥½ pack to <1 pack	10 (6.7)	31 (3.0)	2.4 (1.1–4.9)
≥1 pack	9 (6.0)	42 (4.1)	1.6 (0.7–3.2)
Yes, but unknown	1 (0.7)	11 (1.1)	0.7 (0.1–3.5)
Alcohol			
None	124 (83.2)	801 (78.5)	Ref.
Moderate: >none to <5 drinks/wk	18 (12.1)	198 (19.4)	0.6 (0.3–1.0)
≥5 drinks/wk	4 (2.7)	13 (1.3)	2.0 (0.6–5.7)
Unknown	3 (2.0)	9 (0.9)	2.2 (0.5–7.3)
Child with confirmed major congenital anomaly*	16 (10.7)	31 (2.9)	4.0 (2.1–7.4)
Child birth wt, † mean (SD); g	3,246 (681)	3,366 (608)	1.0 (0.9–1.0)
Child length, † mean (SD); cm	51 (4)	51 (4)	1.0 (1.0–1.1)
Child head circumference, † mean (SD); cm	34 (2)	35 (3)	0.9 (0.8–1.0)

Numbers in parentheses are percentages, except when otherwise noted. SDs were rounded to the nearest decimal. Unadjusted odds ratios did not differ from the adjusted ones that were obtained using multiple linear (continuous variables) or multiple logistic (discrete variables) regression.

* Confirmed by inspection of medical records or interviews with pediatricians by experienced clinical dysmorphologists.

† Excluding stillbirths and fetal deaths.

AED = antiepileptic drug.

EURAP, International Lamotrigine Study) obtain their information from health care professionals. It is likely that the women who participate in the AED Pregnancy Registry do not represent the entire population of pregnant women exposed to AEDs living in North America. The extent of such participation bias has not been determined. Finally, this and other pregnancy individual registries are not designed to study the long-term effects of prenatal exposure to VPA, such as developmental delay and specifically

autism, which has been described as related outcome in two case reports⁴⁰ and one case series.⁴¹ A prospective study would require hundreds of VPA-exposed children and a study design for long-term follow-up, including testing cognitive function, to address these associations with adequate statistical power.

The risk for women taking VPA of having a baby with an NTD is about 2 to 5%.^{17,18,42} Thus, in our sample of 149 VPA-exposed women, two to eight infants with NTD would be expected and three were

observed. The mothers of all 16 cases with congenital anomalies in the VPA-exposed group took either multivitamins containing folic acid or folic acid supplements during the periconceptional period. The three cases with spina bifida were among the 106 VPA-exposed women who took the daily recommended amount of folic acid (prevalence: 2.8%; 95% CI: 0.6 to 8.0%). These findings are in agreement with one case report⁴³ of the occurrence of spina bifida in spite of periconceptional supplementation with folic acid. The dose of folic acid supplementation in each mother of a malformed infant listed in table 1 was, on average, 1.36 mg, with a range of 0.4 to 5 mg. This finding in this case series should not be considered a definitive assessment of whether or not periconceptional supplementation with folic acid prevents the occurrence of spina bifida when the mother is taking VPA as monotherapy. However, recent data⁴⁴ have shown that folic acid supplementation in women taking carbamazepine can reduce the risk of occurrence of spina bifida.

Acknowledgment

The staff of the registry includes a director and teratologist (Lewis B. Holmes, MD), an epidemiologist (Diego F. Wyszynski, MD, MHS, PhD; previously, Ellice Lieberman, MD, DrPH), a geneticist/dysmorphologist (Joan M. Stoler, MD), three neurologists/epileptologists (Edward Bromfield, MD, Daniel Hoch, PhD, MD, and Shahram Khoshbin, MD), a study coordinator (Maya Nambisan, MPH), a director of Marketing and Communications (Caitlin R. Smith, MPH), a research assistant and interviewer (Ivelisse Santos-Rodriguez), an intern research assistant (Rachel Alsdorf), an abstractor and data analyst (Helen Ahn), pharmacist (Lois Parker, RPh), and a consultant in database programming (John Farrell). In addition, the authors thank the staff who helped to develop the registry: Kelly Huntington, Elizabeth Harvey, PhD, Triptaa Surve, MPH, Bridget Riley, Sharon Ng'Ok, Lorrie Walker, Marian Simpson, Fred Sheehan, Amy Cohen, Jonathan Raub, MPH, Kristin Morales, Barbara Jennings, MSW, Sabrina Petersen, Henry Hsu, Amanda Wilson, Adam and Jordan Cusner, and Dena Freedman. Members of the Scientific Advisory Committee are Mark Yerby, MD (chair), Portland, OR; Allen Hauser, MD, New York, NY; Margaret Jacobs, Bethesda, MD; Robert Mitten-dorf, MD, DrPH, Chicago, IL; Janet Cragan, MD, Atlanta, GA; and Lewis Holmes, MD (director of the registry), Boston, MA. The authors thank Vikki Nolan for comments on an earlier version of the manuscript.

References

1. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. *N Engl J Med* 2001;344:1132–1138.
2. Burton BS. On the propyl derivatives and decomposition products of ethylacetoacetate. *Am Chem J* 1882;3:385–395.
3. Henry TR. The history of valproate in clinical neuroscience. *Psychopharmacol Bull* 2003;37:5–16.
4. Owens MJ, Nemeroff CB. Pharmacology of valproate. *Psychopharmacol Bull* 2003;37:17–24.
5. Chadwick DW. Concentration–effect relationships of valproic acid. *Clin Pharmacokinet* 1985;10:155–163.
6. Taylor DM. Prescribing and monitoring of carbamazepine and valproate: a case note review. *Psychol Bull* 2000;24:174–177.
7. Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. *J Pediatr* 1980;97:332–333.
8. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. *Lancet* 1982;2:937.
9. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. The fetal valproate syndrome. *Am J Med Genet* 1984;19:473–481.
10. Clayton-Smith J, Donnai D. Fetal valproate syndrome. *J Med Genet* 1995;32:724–727.
11. Stanley OH, Chambers TL. Sodium valproate and neural tube defects. *Lancet* 1982;2:1282.

12. Robert E, Rosa F. Valproate and birth defects. *Lancet* 1983;2:1142.
13. Nau H, Loscher W, Schafer H. Anticonvulsant activity and embryotoxicity of valproic acid. *Neurology* 1984;34:400–401.
14. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. *Lancet* 1986;1:1392–1393.
15. Oakeshott P, Hunt GM. Valproate and spina bifida. *Br Med J* 1989;298:1300–1301.
16. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. *Neurology* 1992;42:111–118.
17. Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. *Neurology* 1992;42:119–125.
18. Bjerkedal T, Czeizel A, Goujard J, et al. Valproic acid and spina bifida. *Lancet* 1982;2:1096.
19. Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. *Am J Med Genet* 1988;29:171–185.
20. Wyszynski DF, Beaty TH. Review of the role of potential teratogens in the origin of human nonsyndromic oral clefts. *Teratology* 1996;53:309–317.
21. Pandya NA, Jani BR. Post-axial limb defects with maternal sodium valproate exposure. *Clin Dysmorphol* 2000;9:143–144.
22. Rodriguez-Pinilla E, Arroyo I, Fondevilla J, Garcia MJ, Martinez-Frias ML. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. *Am J Med Genet* 2000;90:376–381.
23. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. *Am J Med Genet* 2001;98:168–175.
24. Holmes LB. Teratogen-induced limb defects. *Am J Med Genet* 2002;112:297–303.
25. Stoll C, Audeoud F, Gaugler C, Bernardin A, Messer J. Multiple congenital malformations including generalized hypertrichosis with gum hypertrophy in a child exposed to valproic acid in utero. *Genet Couns* 2003;14:289–298.
26. Holmes LB, Wyszynski DF, Lieberman E, for the AED Pregnancy Registry. The Antiepileptic Drug Pregnancy Registry: a six year experience. *Arch Neurol* 2004;61:673–678.
27. Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. *Teratology* 1999;59:1–2.
28. Nelson K, Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. *N Engl J Med* 1989;320:19–23.
29. Stata Corp.. Stata software, version 8.2. College Station, TX, 2003.
30. Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. *Acta Paediatr* 1996;85:739–746.
31. Ohtsuka Y, Silver K, Lopes-Cendes I, et al. Effect of antiepileptic drugs on psychomotor development in offspring of epileptic mothers. *Epilepsia* 1999;40:296.
32. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. *Epilepsy Res* 1999;33:145–158.
33. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. *J Neurol Neurosurg Psychiatry* 2001;70:15–21.
34. Mawer G, Clayton-Smith J, Coyle H, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. *Seizure* 2002;11:512–518.
35. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. *Neurology* 2003;60:575–579.
36. Lajeunie E, Barcik U, Thorne JA, Ghouzzi VE, Bourgeois M, Renier D. Craniosynostosis and fetal exposure to sodium valproate. *J Neurosurg* 2001;95:778–782.
37. Olafsson E, Hallgrímsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. Pregnancies of women with epilepsy: a population-based study in Iceland. *Epilepsia* 1998;39:887–892.
38. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. *Am J Med Genet* 1997;68:18–24.
39. Fried S, Kozer E, Nulman I, Einarson TR, Koren G. Malformation rates in children of women with untreated epilepsy: a meta-analysis. *Drug Safety* 2004;27:197–202.
40. Williams PV, Hersh JH. A male with fetal valproate syndrome and autism. *Dev Med Child Neurol* 1997;39:632–634.
41. Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. *J Med Genet* 2000;37:489–497.
42. Lindhout D, Meinardi H. Spina bifida and in-utero exposure to valproate. *Lancet* 1984;2:396.
43. Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. *Seizure* 1999;8:253–254.
44. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 2000;343:1608–1614.